PROJECT

Projects

Environmental & Social Review Summary

Project Number

44287

Company Name

JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.

Date ESRS Disclosed

Nov 3, 2020

Country

China

Region

East Asia and the Pacific

Last Updated Date

Sep 20, 2024

Environmental Category

B - Limited

Status

Completed

Previous Events

Approved : Feb 25, 2021
Signed : Mar 12, 2021
Invested : May 17, 2021

Sector

other

Industry

Health, Education and Life Sciences

Department

Regional Industry - MAS Asia & Pac

Project Description

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (“Yuwell” or the “company”) which started operations in 1998 in Danyang, Jiangsu Province, is a leading medical device manufacturer in China (https://www.yuwell.com/index_en.php). Yuwell is listed on the Shenzhen Stock Exchange and has 500+ product categories for home and clinical use. The group’s global manufacturing center is located at Danyang, Jiangsu Development Zone, China. The company has 5 manufacturing bases including 2 in Danyang (Yun Yang: original plant, and He Yang: new plant), one each in Suzhou, Shanghai and Germany; as well as a number of Research & Development (R&D) centers including in Danyang, Suzhou, Shanghai, Nanjing, and Germany. The company produces homecare and medical clinical products including respiratory devices such as ventilators, nebulizers, and oxygen concentrators, and diagnostic devices such as thermometers, glucometers and disinfection products for hospitals. The company plans to substantially increase its production capacity including that of ventilators and oxygen concentrators, through: (1) expanding its key manufacturing base in Danyang in Jiangsu Province, which will involve installation of manufacturing machinery in a new building within the existing He Yang plant footprint, expected to be complete in 2023; and (2) by potentially exploring investments in healthcare related entities in China and in other countries (together the “project”). IFC is proposing a US$150 million A Loan to Yuwell to fund the project, with IFC’s loan proceeds to be used primarily for: (1) the production of COVID-19 related products and capital expenditures at the company’s new plant in He Yang; and (2) with a portion of the proceeds possibly utilized towards supporting the company’s potential future investments (including but not limited to those in areas of research and development) in healthcare entities (which are not located in or linked to Xinjiang province, China, Myanmar, and other fragile and conflict states (FCS) or conflict areas of non-FCS countries)

Overview of IFC's Scope of Review

IFC’s review of this proposed investment consisted of appraising environmental, health and safety (EHS) and social related information submitted by Yuwell including: group business details and expansion plans, corporate policies and procedures on EHS, Human Resources (HR) management, training records, environment monitoring and audit reports, etc. The appraisal included a virtual (video) site visit to Yuwell’s He Yang plant, and discussions with the company’s senior management and those responsible for EHS and HR management via video conferencing during 15-16 September 2020.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan